Onorach Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Onorach Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH470843D
  • |
  • Pages: 41
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Onorach Ltd (Onorach) is a contract research organization that provides clinical support services. The organization service portfolio includes tailored clinical trial support, clinical plan development, protocol design, regulatory, quality management, clinical operations management, patient and subject recruitment, project management, clinical monitoring, statistical analysis and medical report writing services among others. Onorach also provides temperature monitoring, stability testing, drug supplying, placebo sourcing, labeling, packaging, distribution, and pre-clinical and specialized lipid analysis services. The organization's target therapy areas include cardiovascular, cell based therapeutics, CNS, neurology, endocrinology, infectious diseases, oncology, pediatricians, women's health, and other therapeutics areas. It caters to pharmaceutical, biotech and medical device companies. Onorach is headquartered in Dundee, the UK.

Onorach Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Onorach Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Onorach Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Epirus Biopharma Raises USD 36 Million In Series B Venture Financing 12

EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 14

EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 15

Partnerships 16

Polpharma Enters into Agreement with Epirus Biopharma 16

EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 17

Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 18

Licensing Agreements 19

Livzon Mabpharm Amends Licensing Agreement with Epirus Biopharma 19

Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 21

Epirus Amends Licensing Agreement With Sun Pharma For BOW015 22

Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 23

Equity Offering 24

Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 24

Epirus Biopharma Raises USD53 Million in Public Offering of Shares 25

Zalicus Completes First Tranche Of Private Placement Of Shares For USD 2 Million 26

Zalicus Completes Public Offering Of Shares For USD 15 Million 27

Zalicus Completes Second Tranche Of Private Placement Of Shares For USD 9 Million 28

Asset Transactions 29

Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 29

Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 30

Acquisition 31

Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 31

Taro Pharma Acquires Zalicus Pharma 33

Epirus Biopharma Acquires Bioceros for USD14 Million 34

Onorach Acquires RECRI 35

Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 36

Onorach Ltd-Key Competitors 38

Onorach Ltd-Key Employees 39

Onorach Ltd-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41

List of Figures

Onorach Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Onorach Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Onorach Ltd, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Onorach Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Onorach Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Onorach Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Epirus Biopharma Raises USD 36 Million In Series B Venture Financing 12

EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 14

EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 15

Polpharma Enters into Agreement with Epirus Biopharma 16

EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 17

Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 18

Livzon Mabpharm Amends Licensing Agreement with Epirus Biopharma 19

Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 21

Epirus Amends Licensing Agreement With Sun Pharma For BOW015 22

Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 23

Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 24

Epirus Biopharma Raises USD53 Million in Public Offering of Shares 25

Zalicus Completes First Tranche Of Private Placement Of Shares For USD 2 Million 26

Zalicus Completes Public Offering Of Shares For USD 15 Million 27

Zalicus Completes Second Tranche Of Private Placement Of Shares For USD 9 Million 28

Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 29

Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 30

Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 31

Taro Pharma Acquires Zalicus Pharma 33

Epirus Biopharma Acquires Bioceros for USD14 Million 34

Onorach Acquires RECRI 35

Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 36

Onorach Ltd, Key Competitors 38

Onorach Ltd, Key Employees 39

Onorach Ltd, Subsidiaries 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Onorach Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17805
Site License
USD 500 INR 35610
Corporate User License
USD 750 INR 53415

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com